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Abstract  1 
It is a remarkable feature for a retrovirus that an infection with feline leukemia virus 2 
(FeLV) can result in various outcomes. Whereas some cats contain the infection and 3 
show a regressive course, others stay viremic and succumb to the infection within a 4 
few years. We hypothesized, that differences in the infection outcome might be 5 
causally linked to the viral RNA and provirus loads within the host and these loads 6 
therefore may give additional insight into the pathogenesis of the virus. Thus, the 7 
goals of the present study were to follow-up on experimentally infected cats and 8 
investigate tissues from cats with different infection outcomes using sensitive, 9 
specific TaqMan real-time PCR and reverse transcriptase (RT)-PCR.  10 
Nineteen experimentally FeLV-A/Glasgow-1-infected cats were categorized into 11 
having regressive, progressive or reactivated FeLV infection according to follow-up 12 
of FeLV p27 antigen detection in the blood. Remarkably, regressively infected cats 13 
showed detectable provirus and viral RNA loads in almost all of the 27 tested tissues, 14 
even many years after virus exposure. Moreover, some regressively infected cats 15 
reactivated the infection, and these cats had intermediate to high viral RNA and 16 
provirus tissue loads. The highest loads were found in viremic cats, independent of 17 
their health status. Tissues that represented sites of virus replication and shedding 18 
revealed the highest viral RNA and provirus loads, while the lowest loads were 19 
present in muscle and nerve tissues. 20 
A supplementary analysis of 20 experimentally infected cats with progressive 21 
infection revealed a median survival time of 3.1 years (range from 0.6 to 6.5 years); 22 
~70% (n = 14) of these cats developed lymphoma, while leukemia and non-23 
regenerative anemia were observed less frequently.  24 
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Our results demonstrate that the different infection outcomes are associated with 1 
differences in viral RNA and provirus tissue loads. Remarkably, no complete 2 
clearance of FeLV viral RNA or provirus was detected in cats with regressive 3 
infection, even up to 12 years after exposure. In several cases FeLV reactivation could 4 
be observed. Thus, retroviruses integrated as provirus into the host’s genome, could 5 
not be eliminated completely by the host and maintained their full potential for 6 
replication and reactivation. 7 
 8 
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1.1 Introduction 19 
Retroviral infections and their impact on human and animal health are of major 20 
scientific and public interest. It is fundamental to understand the underlying biology 21 
of retroviral infections to develop successful antiviral strategies, such as preventive 22 
and therapeutic measures. Animal models are needed to investigate host-virus 23 
interactions. One established animal model for tumor and retroviral research that has 24 
been used for nearly 50 years is feline leukemia virus (FeLV) infection in cats.  25 
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FeLV is a gammaretrovirus of domestic cats and closely related wild felids [1]. An 1 
infection with the virus may cause severe diseases, including cytoproliferative 2 
disorders, which are characterized by tumor growth and leukemia, or cytosuppressive 3 
diseases with immunodeficiency and myelosuppression. Vaccines against FeLV 4 
infection have been commercially available for almost three decades [1-3] and are 5 
highly effective [4-6].  6 
The discovery of FeLV in 1964 [7] was succeeded by many studies elucidating the 7 
pathogenesis and course of FeLV infection [8-10]. After FeLV exposure, the tonsils 8 
and local lymph nodes in the oropharynx are infected. During early cell-associated 9 
viremia, the virus spreads into the circulating lymphocytes and monocytes, thereby 10 
distributing the virus to lymphoid tissues throughout the body. A significant step 11 
during FeLV infection is infection of the bone marrow (bm), where neutrophil and 12 
platelet precursor cells become virus-positive. With the establishment of persistent 13 
viremia, CD4
+
, CD8
+
 and B lymphocytes, granulocytes and monocytes are infected in 14 
the blood, thereby spreading the virus throughout the body, where it infects many 15 
organs and tissues [11, 12]. 16 
A new cycle of infection starts with the shedding of the virus. Horizontal transmission 17 
mainly occurs directly from cat to cat. In most cases, transmission occurs through 18 
contact with saliva (licking, mutual grooming and sharing of dishes); however, FeLV 19 
may also be transmitted via blood, feces and milk [1, 13-16]. 20 
Until recently, the outcome of FeLV-infected cats was categorized using mainly the 21 
results from virus isolation, immunofluorescence and enzyme-linked immunosorbent 22 
assays (ELISAs). The introduction of new molecular methods, such as the 23 
development of sensitive, specific TaqMan real-time PCR and reverse transcriptase 24 
(RT)-PCR, helped to shed new light on the biology and pathogenesis of retroviral 25 
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infections [4, 17-20]. Using quantitative TaqMan real-time PCR (qPCR) and RT-1 
qPCR, the detection and quantification of provirus and viral RNA was achieved. It 2 
has been demonstrated that the detection of provirus by real-time PCR is a more 3 
sensitive diagnostic marker for identifying FeLV-exposed cats compared to 4 
previously used methods [18]. Thus, the FeLV exposure rates were highly 5 
underestimated for years. In Switzerland, 6% of the Swiss pet cat population was 6 
FeLV p27-positive. However, an additional 10% was provirus-positive with the 7 
absence of detectable antigenemia [18]. These cats must have been exposed to FeLV 8 
but likely recovered from viremia.  9 
It is a remarkable feature of FeLV that an infection with the virus can result in several 10 
different outcomes [9, 10, 13, 21-24]. According to the information of provirus and 11 
plasma viral RNA loads, the host-response categories were refined and described as 12 
follows. The absence of FeLV provirus, virus and antigen after challenge was 13 
categorized as abortive infection [20, 25-27]. Cats classified as having experienced an 14 
abortive infection may not be distinguished from those never exposed to FeLV on the 15 
basis of p27 ELISA and real-time PCR of blood and tissues [20]. In some cats that 16 
had undergone low-dose exposure, seroconversion was detected as a sign of FeLV 17 
infection by means of the feline oncornavirus-associated cell membrane antigen assay 18 
[27]. Cats with regressive infection show either transient or undetectable antigenemia. 19 
They develop an efficient immune response with neutralizing antibodies [28, 29] and 20 
FeLV-specific cytotoxic T lymphocytes [18, 30, 31]. It was demonstrated that cats 21 
undergoing regressive infection display provirus and plasma viral RNA loads similar 22 
to those in cats with progressive infection during the first week after infection. 23 
However, they manage to reduce plasma viral RNA and provirus loads to moderate or 24 
low levels, while the loads in cats with a progressive infection remain high [18, 26]. 25 
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Viral RNA loads in cats with regressive infection may or may not be cleared below 1 
detectable levels in the blood [32]. Approximately one-third of all infected cats 2 
become persistently viremic [33]. These cats were shown to have constantly high 3 
provirus and plasma viral RNA loads. The cats lack effective FeLV-specific humoral 4 
and cellular immunity [1, 34], and they ultimately succumb to FeLV-associated 5 
diseases within some years of infection [35]. 6 
Reactivation of FeLV infection in aviremic cats (p27-negative, but provirus positive) 7 
with and without immune suppression has been reported in several studies [15, 26, 8 
36-39]. The study by Pedersen et al. (1984) compared the reactivation of latent FeLV 9 
infection after methylprednisolone administration: FeLV Rickard was the easiest to 10 
activate compared to an isolate from a leopard cat (CT600-FeLV) and the Snyder-11 
Theilen strain (ST-FeLV) [37]. Thus, the potential for reactivation seemed to be 12 
associated with the FeLV isolate [37]. In the absence of experimental immune 13 
suppression, only a limited number of cases of reactivation of FeLV infection have 14 
been reported [15, 20, 26, 36, 37]. In some of these cats, natural stress was thought to 15 
be the initiator of reactivation [37]; in another cat, the breakdown of the immune 16 
system as a result of end-stage feline immunodeficiency virus (FIV) initiated FeLV 17 
reactivation [36].  18 
We hypothesized that differences in the infection outcome of FeLV-infected cats 19 
might be causally linked to differences in viral RNA and provirus loads, not only in 20 
the blood but also in tissues. Most FeLV pathogenesis studies were conducted prior to 21 
the development of sensitive, specific qPCR and RT-qPCR for the detection and 22 
quantification of FeLV provirus and viral RNA loads [32]. Thus, it was the aim of this 23 
study to follow-up on experimentally infected cats and to employ sensitive molecular 24 
methods to investigate tissues from cats with different infection outcomes to gain 25 
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better insight into FeLV pathogenesis, its target tissues and the influence of the viral 1 
distribution on the outcome of the infection. In particular, 27 tissues from 19 2 
experimentally FeLV-infected cats with different duration and outcome of infection 3 
were investigated for the presence and quantity of FeLV provirus and viral RNA.  4 
 5 
2.1 Methods 6 
2.1.1 Sample description 7 
All specific pathogen-free (SPF) cats included in this study were in experimental 8 
studies officially approved by the veterinary office of the Swiss Canton of Zurich 9 
(197/89, 43/90, 66/91, 131/91, 329/91, 56/95, 30/2003, 59/2005, 99/2007, 11/2011 10 
and 160/2010). The cats were kept in groups under optimal ethological conditions as 11 
previously described [40]. The cats had been experimentally infected with FeLV-12 
A/Glasgow-1 in the above-mentioned studies [4, 5, 26, 36, 40-43] and were 13 
euthanized for reasons unrelated to the present study. 14 
The 19 cats in the tissue-load study showed different FeLV infection outcomes and 15 
were grouped into four response categories. The first response category, consisting of 16 
four persistently viremic cats (#15, #23, #64, #R1, ages 0.6 to 1.3 years) that were 17 
infected for less than 1 year and did not have symptoms at the time of euthanasia, was 18 
termed “viremic healthy” [4, 41]. The second category included another five 19 
persistently viremic cats (#19, #32, #67, #B1 and #B3, ages 2.6 to 4.5 years) that were 20 
infected for more than 2 years and developed disease due to FeLV-related lymphoma 21 
were named “viremic ill” [4, 42]. The third category “regressive” contained five 22 
clinically healthy cats (#68, #258, #260, #271 and #B9, ages 2.9 to 13.8 years) with a 23 
regressive infection and transient or undetectable antigenemia [4, 5, 42]. Response 24 
category four “reactivated” included five cats (#30, #70, #HBU1, #GCN4 and #261, 25 
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ages 0.7 to 9.6 years) that showed either undetectable or transient viremia after 1 
experimental infection but then reactivated [4, 5, 26, 36, 40, 43](Table 2). Cat #30 2 
was co-housed with cats that had become persistently infected [26]. The other four 3 
cats, had not been exposed to persistently infected cats for several weeks to years: Cat 4 
#HBU1 was housed with regressively infected cats only [43], cat #GCN4 was 5 
separated from persistently infected cats 45 weeks before reactivation [40], in cat 6 
#261 and cat #70, the last potential exposure to FeLV was 18 month and 46 weeks 7 
prior to FeLV reactivation, respectively [26, 36]. The following 27 tissues were 8 
collected upon necropsy: thyroid, bm, mesenteric lymph node (ln.), popliteal ln., 9 
sternal ln., submandibular ln., spleen, tonsil, thymus, parotid gland, mandibular gland, 10 
duodenum, ileum, jejunum, colon, rectum, brain, sciatic nerve, spinal cord, kidney, 11 
urinary bladder, aorta, diaphragm, femoral muscle, myocardium, lung and liver. In 12 
addition, tumor tissue was investigated if present and categorized as described [44]. 13 
All tissues were collected immediately after euthanasia, snap frozen in liquid nitrogen 14 
following collection and stored at -80°C until nucleic acids were extracted.  15 
In addition, information on 20 persistently FeLV-A/Glasgow-1-infected cats was used 16 
to assess the duration and clinical outcome of an average persistent FeLV infection in 17 
SPF cats. This group of cats included the 5 persistently infected cats (group 2 termed 18 
“viremic ill”) in the tissue load study (Table 2) as well as 15 additional cats fitting this 19 
category (Table 1). 20 
2.1.2 Serological assays and virus isolation 21 
FeLV viremia was determined by p27 sandwich ELISA as described [45]. Values 22 
above 4% of the positive control (culture supernatant of FL-74 feline lymphoblastoid 23 
cell line permanently infected with FeLV) were considered positive [4]. According to 24 
the European Pharmacopoeia (2005), a cat was considered persistently infected when 25 
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it was FeLV p27-positive for three consecutive weeks or on five occasions between 1 
weeks 3 and 15 post-exposure. 2 
The presence of infectious FeLV was determined in vitro by inoculation of 3 
heparinized plasma samples onto QN10S cells [46]. 4 
To detect FeLV latency, bm was cultured in the presence of hydrocortisone [5].  5 
2.1.3 Nucleic acid extractions and cDNA production 6 
Genomic DNA (gDNA) and RNA were extracted from tissues as previously described 7 
[47, 48]. For all RNA and DNA extractions, negative controls consisting of 100 µl of 8 
phosphate buffered saline were prepared for each batch to monitor cross-9 
contamination. According to earlier results levels of gDNA contamination in RNA 10 
extractions were < 1% [47]. 11 
The quality of the RNA extraction was tested by real-time RT-PCR, with the Reverse 12 
Transcriptase qPCR Mastermix (Eurogentec, Seraing, Belgium). For this purpose, 5 13 
μl of extracted RNA or RNA standard was amplified in a total reaction volume of 25 14 
µl with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers and probe 15 
[49]. For samples with GAPDH concentrations higher than 10,000 copies per reaction 16 
and a negative extraction control, the RNA was reverse transcribed into 17 
complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription 18 
Kit (Applied Biosystems, Rotkreuz, Switzerland) and random primers according to 19 
the manufacturer’s instructions.  20 
2.1.4 TaqMan fluorogenic real-time PCR assay 21 
gDNA and cDNA were amplified and quantified on a Rotor-Gene 6000 real-time 22 
rotary analyzer (Corbett, Mortlake, Australia) or an ABI Prism 7700 sequence 23 
detection system (Applied Biosystems). 24 
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FeLV viral loads from all three subtypes of FeLV, -A, -B, and -C, but not endogenous 1 
FeLV, were amplified from cDNA or gDNA using TaqMan real-time PCR (U3 2 
region) as previously described [19]. FeLV viral RNA loads were normalized to two 3 
reference genes: GAPDH [49], the most commonly used reference gene, and 4 
ribosomal protein S7 (RPS7), the best reference gene for various feline tissues [47].  5 
Because two LTR U3 target sequences are present for each provirus copy, the number 6 
of provirus copies was calculated by dividing the number of copies of U3, as 7 
determined by real-time PCR, by two. This number of provirus copies was then 8 
divided by the number of feline albumin (fALB) copies measured by real-time PCR, 9 
as described previously [48], to determine the provirus copy numbers per cell. 10 
2.1.5 Statistics 11 
For statistical analysis, the tissues were integrated into physiological tissue groups 12 
(Table 3). Statistical analyses were performed using GraphPad Prism for Windows, 13 
Version 5.03 (GraphPad software, San Diego, CA). Differences among three and 14 
more groups were analyzed by the non-parametric Kruskal–Wallis one way ANOVA 15 
by Ranks (pKW) for unpaired samples or the non-parametric Friedman test for paired 16 
samples (pF) followed by the Dunn’s Multiple Comparison test (pD). Differences 17 
between two groups were tested for significance using the non-parametric Mann-18 
Whitney U-test for unpaired samples (pMWU) or the Wilcoxon signed rank test for 19 
paired samples (pW). Loads (viral RNA and provirus) were analyzed using the 20 
Spearman rank test for correlation. Moreover, the association between the “major 21 
diagnosis at necropsy” and the age of the cat at infection (categorized in “young” [< 1 22 
year] and “older” [≥ 1 year]) was tested by Chi-square test (pChi). A p-value less than 23 
0.05 was considered significant. 24 
 25 
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3.1 Results  1 
3.1.1 Long-term observation: duration and clinical outcome of experimentally 2 
persistent FeLV-A/Glasgow-1 infection 3 
Currently, only limited data are available on the survival times and terminal outcome 4 
of infection of experimentally FeLV-infected cats [26, 50, 51]. In our SPF facility, 5 
some cats persistently infected with FeLV showed remarkably long survival times, 6 
while others succumbed to infection quickly. To substantiate and assess this 7 
observation, we summarized data available on 20 cats that had been experimentally 8 
exposed to FeLV-A/Glasgow-1 and had developed persistent infection. Persistently 9 
viremic cats lived an average (median) of 3.1 years with FeLV infection (0.6 – 6.5 10 
years, n = 20) before they had to be euthanized for humane reasons (Table 1). The 11 
major diagnosis at necropsy included lymphoma (70%), leukemia (15%) and non-12 
regenerative anemia (15%). Significant differences in the survival time could be 13 
shown between cats with different outcome (pKW: 0.0212): cats that developed a 14 
lymphoma survived an average of 3.6 years with the infection (from 1.6 to 6.5 years; 15 
n = 14), whereas cats that showed non-regenerative anemia lived an average of only 16 
0.6 years (from 0.6 to 1.1 years; n = 3; pMWU = 0.0098). The three cats that suffered 17 
from leukemia survived longest (median: 5.3 years, from 1.8 to 5.3 years; n = 3). We 18 
investigated whether the age at infection had an effect on the survival time. The cats 19 
included in this study had been infected between the ages of 10 and 59 weeks (Table 20 
1). No correlation was found between the age at infection and the survival time of the 21 
cats (data not shown). Moreover, cats with different major diagnosis at necropsy 22 
(lymphoma, leukemia, anemia) did not differ significantly in the age at infection (pKW 23 
= 0.8077) and cats infected at the age < 1 year did not have different major diagnosis 24 
at necropsy compared with cats infected at the age of ≥ 1 year (pChi = 0.5471). 25 
 - 13 - 
3.1.2 Tissue load study: categorization of cats 1 
In the tissue load study, 19 FeLV-infected cats with various infection outcomes were 2 
included (Table 2). Terminally collected plasma samples were examined for the 3 
presence of FeLV p27 capsid antigen by ELISA. The cats were grouped into four 4 
categories: regressive, reactivated, viremic ill and viremic healthy. Significant 5 
differences were found among the four categories (Fig. 1A; pKW = 0.0019). Highest 6 
terminal p27 levels were detected in plasma samples from viremic ill cats that had 7 
developed lymphoma, whereas negative levels were found - per definition - in cats 8 
with regressive infection (Fig. 1A; Supplementary Fig. 1). Viremic ill cats had 9 
significantly higher p27 antigen blood loads than viremic healthy cats (pMWU = 10 
0.0159; Supplementary Fig. 1). Cats, that reactivated the infection and developed 11 
FeLV-associated disease had intermediate p27 loads (between the categories 12 
regressive and viremic ill), similar to viremic healthy cats (Fig. 1).  13 
3.1.3 Follow-up of cats with reactivation of FeLV infection 14 
Cats with reactivated FeLV infection were of particular interest, but only a few 15 
studies that have observed the cats throughout infection and reactivation are available. 16 
In the tissue load study, we included five cats with reactivated FeLV infection. For 17 
two cats (cats #30 and #GCN4), p27 antigen ELISA, virus isolation from blood and 18 
virus isolation from bm in the presence of hydrocortisol (test for latency) were 19 
negative at the tested time points [26, 40] until the infection was reactivated in both 20 
cats. Cat #30 became FeLV antigen-positive in week 44 post infection (p.i.), with 21 
increasing antigen levels thereafter (Fig. 1B) and showed a lymphoma in the thymus 22 
at the time of euthanasia, 10 weeks later [26] (Table 2). Cat #GCN4 developed a 23 
CD3
+
 T-cell lymphoma of the thymus, mediastinum and the sternal ln and was found 24 
to be p27-positive at the time of euthanasia, 1.2 years p.i. (Fig. 1B and Table 2 [40]). 25 
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The three remaining cats in this category (#HBU1, #261 and #70) were all transiently 1 
p27-positive one to several time points after FeLV infection (between week 2 and 7), 2 
but subsequently cleared the antigenemia (Fig. 1B). The infection was reactivated 3 
between 0.5 and 8.5 years after the initial infection. In cat #HBU1, FeLV latency was 4 
detected by bm culture 17 weeks p.i.. At week 26, the animal was highly positive for 5 
FeLV p27 (113%; [Fig. 1B]) and had developed a lymphoma in the thymus, 6 
mesenteric ln., liver, kidney and bm with secondary leukemia (white blood cell count 7 
49 × 10
3 
cells/µl with 75% lymphoblasts [Table 2]).  8 
Cat #261 was described in detail elsewhere [36]. Briefly, in addition to the FeLV-9 
A/Glasgow-1 infection, the cat was co-infected with FIV. After the cat had become 10 
p27-negative, no latency could be detected by bm culture. At the age of 9.6 years, the 11 
cat had developed severe non-regenerative anemia, leukopenia and a multicentric 12 
lymphoma (Table 2). Simultaneous with disease development, the cat again became 13 
FeLV p27 antigen-positive [36] (Fig. 1B). 14 
Finally, in cat #70, latent infection was detectable by bm culture collected at week 17 15 
p.i. but not anymore at week 43 p.i.. Concurrent with the reactivation of FeLV 16 
infection during week 101, a lymphoma in the thymus, tonsil, spleen, kidney and 17 
various ln. was detectable [26] (Fig. 1B and Table 2). 18 
3.1.4 FeLV viral RNA loads in tissues of cats with different infection outcome 19 
The exogenous FeLV tissue loads, measured by RT-qPCR, were compared among the 20 
categories with different infection outcome. Overall, significantly lower viral RNA 21 
loads were found in cats with a regressive course of infection compared to viremic 22 
cats, healthy or ill, and cats with reactivation of infection (Fig. 1C; pKW < 0.0001). In 23 
detail, the quantification of viral RNA in 27 tissues from cats with different infection 24 
outcome showed detectable loads in nearly all investigated tissues, (Fig. 2, 25 
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normalization depicted with RPS7, normalization with GAPDH not shown). The cat 1 
category, classified as having a regressive infection, showed the lowest loads of FeLV 2 
viral RNA (Fig. 2A). Nonetheless, FeLV viral RNA was detectable in most tissues 3 
from at least some of the cats in this category, with the exception of five tissues (the 4 
sciatic nerve, spinal cord, urinary bladder, diaphragm, and aorta; Fig. 2A). Viral RNA 5 
could be found in all tissues from all cats in the other infection outcome categories 6 
(Fig. 2B-D), with the exception of only three samples (Fig. 2B). A comparison 7 
between all tissues within each category revealed only statistically significant lower 8 
FeLV loads in the femoral muscle of viremic cats, when compared with the 9 
mandibular gland and the duodenum (Fig. 2D; pD < 0.05).  10 
When comparing different tissues, the highest FeLV viral RNA loads were found in 11 
the intestinal tract, lymphoid tissues and salivary glands, whereas the lowest loads 12 
were detected in the nervous system. This finding was confirmed and found to be 13 
statistically significant when comparing the FeLV viral RNA loads in single tissues of 14 
all FeLV viremic cats (viremic healthy and viremic ill combined; pF < 0.0001). 15 
Significantly higher FeLV loads were found in the duodenum than in the spinal cord, 16 
kidney, femoral muscle (pD < 0.01), brain, sciatic nerve and myocardium (pD < 0.05). 17 
In addition, the FeLV viral RNA load in the mandibular gland was significantly 18 
higher than in the femoral muscle (pD < 0.01) and spinal cord (pD < 0.05). 19 
Furthermore, a significant difference was detected between the FeLV viral RNA loads 20 
in tonsils and the femoral muscle (pD < 0.05, data not shown).  21 
The investigated tissues were also categorized into functional tissue groups (Table 3). 22 
The FeLV viral RNA loads were compared between functional tissue groups in the 23 
four response categories; a tendency was observed, with the lowest loads in cats with 24 
regressive outcome < reactivated < viremic healthy ≤ viremic ill, and was independent 25 
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of the reference gene used for normalization (for representative examples, see Fig. 3A 1 
and B). All investigated functional groups showed statistically significant differences 2 
between regressive and viremic ill cats; viremic ill cats had approximately 1000-times 3 
higher loads compared to regressive cats (for representative examples, see Fig. 3A 4 
and B). Whereas, viral RNA loads were clearly lowest in samples obtained from cats 5 
with a regressive infection, the loads from the reactivated tissue group often revealed 6 
similar levels to the samples obtained from cats undergoing a viremic infection (for a 7 
representative example, see Fig. 3B). 8 
The FeLV viral RNA load was also compared between the response categories in 9 
single tissues, confirming the tendency observed in functional tissue groups, with the 10 
lowest loads in regressive and highest loads in viremic ill cats (for representative 11 
examples, see Fig. 3C and D). The variability in viral RNA loads in a single tissue 12 
was highest between different cats of the regressive category (data not shown). 13 
3.1.5 FeLV provirus loads in tissues of cats with different outcome 14 
Analogous to the quantification of FeLV viral RNA loads in cats with different FeLV 15 
infection outcomes, the provirus loads were also quantified. To determine the cell 16 
number of the input gDNA, FeLV provirus copy numbers were normalized to fALB 17 
[48]. In contrast to the results of the FeLV viral RNA loads, FeLV provirus was 18 
detectable in some samples from each investigated organ, although no provirus was 19 
found in a few single samples (22 of 459 measurements), which was indicative of 20 
provirus numbers around the detection limit. Similar to the results of the FeLV viral 21 
RNA loads, provirus loads were highest in the intestinal tract and lymphoid tissues, 22 
whereas the lowest FeLV provirus loads were detected in the nervous system (Fig. 4). 23 
In addition, overall, the provirus loads were lowest in cats with regressive FeLV 24 
infection, followed by cats with reactivated infection (intermediate loads) and viremic 25 
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cats (highest loads, Fig. 1D). In the category of the viremic healthy cats, statistically 1 
higher FeLV provirus loads were detected in the bm compared with the brain and 2 
urinary bladder (pD < 0.05; Fig. 4C). In the viremic ill response category, a 3 
significantly lower FeLV provirus load was found in the brain compared to sternal ln. 4 
(pD < 0.01), bm, mesenteric ln., spleen, mandibular gland and jejunum (pD < 0.05; 5 
Fig. 4D).  6 
Comparisons between the four response categories in specific functional tissue groups 7 
confirmed the tendency of lowest provirus loads in cats with regressive outcome < 8 
reactivated < viremic healthy ≤ viremic ill (for representative examples, see Fig. 5A 9 
and B). Statistically significant differences were found between regressive and 10 
viremic ill cats for all investigated functional groups. Differences between the 11 
medians of viremic ill and regressive tissue groups always exceeded four orders of 12 
magnitude.  13 
FeLV provirus loads in single tissues of the four response categories were compared, 14 
confirming the lowest levels in samples from the category of regressive cats (for 15 
representative examples, see Fig. 5C and D). The provirus loads in samples from the 16 
reactivated category were mainly found to be between those of the regressive and 17 
viremic categories, with some reaching levels as high as those detected in the viremic 18 
category. 19 
 20 
3.1.6 Correlation between viral RNA and provirus loads 21 
Spearman correlation coefficients were determined to assess the linear relationship 22 
between viral RNA and provirus loads. When all tissues from all cats were included, a 23 
linear relationship between viral RNA and provirus loads was identified (413 samples 24 
analyzed, r = 0.8500, p < 0.0001; Supplementary Fig. 2A). When single tissues were 25 
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analyzed, the strongest linear relationship was found in the mandibular gland (n = 16, 1 
r = 0.9617, p < 0.0001).  2 
Ratios between viral RNA and provirus loads were compared between the different 3 
response categories. Significantly lower viral RNA/provirus ratios were detected in 4 
cats with a regressive course of infection compared with the other response categories 5 
(pKW < 0.001; Supplementary Fig. 2B). In these cats, the virus might not be 6 
replicating as actively as in the other categories. In addition, significant differences in 7 
the ratios of the viral RNA and provirus loads were also found when viremic ill cats 8 
were compared with viremic healthy or reactivated cats (pKW < 0.05; Supplementary 9 
Fig. 2B). 10 
 11 
3.1.7 FeLV viral RNA and provirus loads in tumor tissue 12 
FeLV viral RNA and provirus loads in tumors from viremic ill and reactivated cats 13 
were compared with the respective healthy tissue. No statistically relevant difference 14 
was found for provirus or viral RNA loads between the healthy and tumor tissue 15 
groups (data not shown).  16 
 17 
4.1 Discussion  18 
This is the first study to systematically measure the viral RNA and provirus tissue 19 
loads in cats with different FeLV infection outcomes. Differences were detected in the 20 
viral RNA and provirus tissue loads among the different response categories. While 21 
the cats with regressive infection remarkably had detectable viral RNA loads in many 22 
tissues, this category of cat was found to have lowest viral RNA and proviral tissue 23 
loads, the highest loads were found in the cats that had undergone progressive 24 
infection, independent of the health status. The fact that FeLV was detectable in the 25 
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form of viral RNA and DNA in most examined tissues of regressive cats has 1 
important implications for retrovirus research as well as for clinicians who need to 2 
expect reactivation of FeLV in these cats. The biological importance of provirus-3 
positive cats has been neglected for decades – due to unawareness of the subject 4 
(inability to detect these cats using older methods). Our results emphasize that 5 
regressive cats need to be considered if the aim is to further decrease FeLV infection 6 
in the domestic cat population.  7 
We also analyzed the life expectancy of persistently infected cats after experimental 8 
FeLV infection. Persistently infected cats lived an average of 3.1 years before they 9 
were euthanized for humane reasons (development of FeLV-associated fatal diseases). 10 
It had been reported that the life expectancy of experimentally FeLV-infected animals 11 
greatly depends on the virus strain, route of infection and age and thus may vary 12 
significantly [52]. For example, this has been shown for neonatal cats that were 13 
inoculated with different FeLV-plasmid DNA; plasmid DNA from the Rickard strain 14 
(pFRA) resulted in an average survival of 49 weeks p.i., whereas the survival time for 15 
neonates inoculated with pF6A, a molecular clone of subgroup A FeLV which is 16 
considered to be highly infectious but weakly pathogenic, was over 67 weeks [52]. In 17 
the current study, the average life expectancy of the cats after FeLV-A/Glasgow-1 18 
infection was similar to that of naturally FeLV-infected, which was reported to be 2.4 19 
years in a large study of Levy et al. [53] and 3 to 4 years by McClelland and collegues 20 
[35]. Some cats lived up to 6.5 years with persistent FeLV-infection in the present 21 
study. Our results extend previous findings and show that the period until cats develop 22 
FeLV-associated disease may be several years [35]. A persistent FeLV infection 23 
should never be a death sentence per se for the infected cat. However, it needs to be 24 
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considered that persistently infected cats are constant virus shedders and therefore 1 
must be kept isolated from non-infected cats to prevent infection.  2 
The viral RNA and provirus tissue loads in persistently infected cats of different 3 
health status did not differ significantly. However, when we calculated the viral RNA 4 
to provirus ratio, viremic healthy cats had significantly lower ratios than viremic ill 5 
cats (Supplementary Fig. 2B). The higher ratio in cats that had developed FeLV-6 
associated diseases may be indicative of a higher degree of viral replication, which 7 
would be in agreement with the higher levels of FeLV p27 antigen that were found in 8 
the blood of viremic diseased cats compared to viremic healthy cats. Because FeLV 9 
p27 levels in the blood may be easily determined by quantitative p27 ELISA, 10 
following this parameter in persistently infected cats over time may be a predictor of 11 
imminent, FeLV-associated, fatal disease and thus helpful to practitioners and cat 12 
owners. 13 
Compared to viremic cats, cats with regressive infection survived even longer and did 14 
not develop FeLV-associated disease. Three of the five cats from the regressive group 15 
were infected with FeLV for more than 12 years prior to the end of the experiment 16 
(Table 2). During the final 6.2 years of the study, they lived in a cohort of only 17 
provirus-positive, but p27-negative cats. Thus, although these cats had definitely not 18 
been re-exposed to FeLV for over 6 years, FeLV was still detectable in most of their 19 
tissues. It has been postulated that the provirus continuously boosts the FeLV-specific 20 
immune response in these cats [4]. Indeed, some of these cats showed high anti-FeLV 21 
antibody levels, even many years after FeLV exposure (KHH unpublished 22 
observations).  23 
In the present study, several cats with regressive FeLV infection showed reactivation 24 
of FeLV infection during the observation period. Most tissue samples from 25 
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reactivated cats showed intermediate viral RNA and provirus tissue loads, with loads 1 
between those of the cats with regressive and persistent infection. It must therefore be 2 
assumed that the tissue loads of regressively infected cats increased prior to or upon 3 
reactivation of the virus. This hypothesis could be addressed in a future, prospective 4 
experiment using repeated fine needle aspirates from organs (e.g., lymph nodes) or a 5 
collection of bone marrow samples from cats with regressive infection over time to 6 
evaluate tissue loads as a predictive factor of the outcome of infection (i.e., imminent 7 
reactivation).  8 
Viral RNA and provirus loads varied significantly between the different tissues that 9 
were analyzed, with the highest loads in the lymphatic tissues, intestinal tract and 10 
salivary glands. The high viral RNA loads that were measured in lymphoid tissues 11 
indicate that leukocytes are a target of infection and a site of replication, as described 12 
previously [8-11]. The other tissues that showed high viral RNA loads all contained 13 
mucosal or glandular epithelial tissues, which seemed to be favored sites of viral 14 
replication. It should be noted that the tissues might have contained some FeLV 15 
provirus and viral RNA due to the blood supply in the tissues. High blood loads may 16 
particularly be expected in viremic cats, and lower loads may be expected in 17 
regressive cats [4, 6, 20, 26, 54]. It would have been helpful to measure the blood 18 
loads in the individual cats so that the copy numbers due to blood supply could have 19 
been calculated as suggested, e.g., for bacterial hemoplasma infections [55]. 20 
Unfortunately, no terminal blood samples were available for these analyses. 21 
Interestingly, a strong correlation was found between the viral RNA and provirus 22 
loads in tissues from cats (r = 0.843, p < 0.0001). A similar observation has been 23 
described for the viral RNA and provirus loads in the blood during the course of 24 
experimental FeLV infection [19, 56]. In addition, it has been shown that the FeLV 25 
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provirus load in peripheral blood correlates with the disease outcome in experimental 1 
FeLV infection [18, 26, 56]. In the study of Hofmann-Lehmann and colleagues 2 
(2001), a comparison of provirus loads and p27 antigen status in blood samples from 3 
597 Swiss cats was performed. A 300-fold higher mean provirus load was found in 4 
cats testing positive for p27 antigen and provirus compared to cats testing negative for 5 
p27 and positive for provirus. A later comparison of the response categories in 6 
experimentally infected cats revealed that in the first week after infection, regressive 7 
and viremic cats had similar provirus and viral RNA loads, whereas the results from 8 
later time points were in agreement with our findings for tissue samples of 1,000- to 9 
10,000 fold differences between the categories [26]. Thus, the association between 10 
FeLV provirus load in blood and outcome of infection can now be shown for viral 11 
RNA and provirus loads in tissue and outcome of infection.  12 
The investigation was conducted as a retrospective study, including several cats which 13 
had been vaccinated previously. Earlier studies have shown that even effective 14 
vaccines do not lead to sterilizing immunity and that the FeLV loads in successfully 15 
vaccinated cats resemble those of cats with naturally contained infection. Moreover, 16 
cats that were not protected by vaccination from progressive infection showed the 17 
same infection outcome as unvaccinated cats with progressive infection [4, 5]. The 18 
influence of the vaccine is thus mainly within the first days or weeks after virus 19 
exposure, when either a contained or progressive infection will prevail; eight weeks 20 
after infection the outcome of infection is established [20] – and most likely not 21 
influenced by the vaccine anymore. Nonetheless, we compared the duration of FeLV-22 
infection in persistently viremic cats in the current study between vaccinated and non-23 
vaccinated cats. No significant difference could be detected (pMWU = 0.4580). 24 
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Interestingly, reactivation of FeLV infection was observed in several cats reported 1 
herein, including cats that were never positive for p27, and in virus isolation from the 2 
blood or bone marrow at the tested time points. However, it cannot be excluded that 3 
some positive time points were missed, because cats were usually only sampled 4 
weekly. Previously, it had been hypothesized that the persistence of plasma viral RNA 5 
in cats with regressive infection might be a prognostic marker for subsequent 6 
reactivation; the viral RNA might have originated from minimal viral replication in a 7 
sequestered tissue [26]. In the current study, blood samples for RNA determination 8 
were only available from the first 15 weeks of infection. Analysis of these samples 9 
showed that plasma viral RNA loads in cats with regressive infection were lower than 10 
those of viremic cats but higher than in regressive cats that did not reactivate infection 11 
(data not shown). 12 
The time point of reactivation is one of the interesting features of cats with regressive 13 
infection. Although the five cats showing reactivation in the present study had been 14 
experimentally infected with FeLV-A/Glasgow-1, they were clinically healthy until 15 
shortly before reactivation. The duration of infection until reactivation was highly 16 
variable among the different cats and ranged from 0.5 to 1.9 years [4, 26, 40, 43], not 17 
including a FIV-coinfected cat, which reactivated infection 8.5 years after the FeLV 18 
exposure/infection [36]. The trigger for virus reactivation could not be determined 19 
because these cats had not undergone a stressful procedure nor had they been immune 20 
suppressed, with the exception of the FIV-infected cat [36]. The differences between 21 
the p27 levels that were detected at the time of euthanasia might be explained by the 22 
time point chosen for their euthanasia.  23 
We included several cats that developed lymphoma after experimental FeLV-24 
A/Glasgow-1 infection. Cats are believed to be the species with the highest incidence 25 
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of lymphoma [57], with approximately 22% of FeLV-antigen positive cats developing 1 
lymphomas [58]. Due to mass testing, elimination and quarantine programs as well as 2 
the broad usage of FeLV vaccines, the estimates of the prevalence of FeLV-associated 3 
types of lymphomas have decreased [57]. We speculated whether tumor tissue from 4 
persistently FeLV-infected cats might be experiencing higher loads of FeLV than 5 
non-tumor tissue. The tissue loads previously described in one cat with reactivated 6 
infection, suggested higher loads in tumor tissues of a multicentric lymphoma 7 
compared to non-tumor tissues [36]. However, in that study, no comparison between 8 
tumor and non-tumor tissue within the same organ was possible. Our results show no 9 
statistically significant differences between viral RNA and provirus loads of tumor 10 
and the respective non-tumor tissue (data not shown, n = 10 for viral RNA, n = 13 for 11 
provirus). This may indicate that not difference in viral RNA or provirus loads are 12 
associated with the induction of lymphomas but that other mechanisms, such as 13 
activating cellular oncogenes at the site of provirus integration, might be sufficient to 14 
induce lymphoma [59]. 15 
 16 
5.1 Conclusions  17 
Determination of viral RNA and provirus loads in tissues of FeLV-infected cats 18 
provided valuable information toward a better understanding of pathogenesis and 19 
infection outcome. Moreover, these results add new evidence concerning the question 20 
whether FeLV can be cleared by the immune system of the host over time. 21 
Remarkably, FeLV was detectable in the majority of tissues from regressive cats in 22 
the present study, demonstrating persistence of FeLV, even many years after virus 23 
exposure. We assume that the virus maintains the potential for replication, because 24 
provirus as well as viral RNA was found in these cats. The immune system of cats 25 
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with regressive infection continuously and effectively suppresses viral replication to a 1 
minimum. Should the immune system fail, the infection may reactivate, even many 2 
years after FeLV exposure, as had been demonstrated in the exceptional case of a cat 3 
co-infected with FIV 8.5 years after FeLV infection. Future studies should further 4 
characterize the immune response that keeps this retrovirus infection successfully and 5 
persistently in check, particularly of cats with regressive infection. 6 
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Figures 1 
Figure 1  – FeLV p27 antigen, viral RNA and provirus loads in cats with 2 
different infection outcome. 3 
A) Comparison of FeLV p27 antigen levels in the different FeLV response categories 4 
as determined by ELISA. B) Time course of FeLV infection in cats with reactivation 5 
after regressive infection. Comparison of the FeLV viral RNA load (C) and provirus 6 
load (D) in tissues from cats of different response categories. A) and B) Results are 7 
represented as percentages of a defined positive control (plasma sample from a 8 
persistently FeLV-infected cat), which was considered 100%. Samples reaching > 4% 9 
of the positive control signal were considered positive [4]. FeLV p27 antigen levels 10 
were tested for significant differences by Kruskal-Wallis one-way ANOVA by Ranks 11 
(pKW as indicated) and subsequently by Dunn's post test: * = p < 0.05; ** = p < 0.01; 12 
*** = p < 0.001. C) and D) The data are shown as box plots; the boxes extend from 13 
the 25
th
 to 75
th
 percentiles. The horizontal line represents the median, and the 14 
whiskers extend from the smallest to the largest value. 15 
Figure 2  - FeLV viral RNA loads in tissues from cats in different FeLV response 16 
categories. 17 
The FeLV viral RNA loads in 27 different tissues collected during necropsy from 18 
FeLV-infected cats in four response categories were quantified using real-time RT-19 
PCR: A) regressive cats, B) cats with reactivated infection, C) viremic healthy cats 20 
and D) viremic ill cats. The FeLV viral RNA load was normalized to the reference 21 
gene RPS7. Similar results have been obtained with normalization to the copies of 22 
GAPDH cDNA (data not shown). The data are shown as box plots, and the boxes 23 
extend from the 25
th
 to 75
th
 percentiles. The horizontal line represents the median, and 24 
the whiskers extend from the smallest to the largest value. The grey shading in the 25 
boxes indicates the presence of a complete dataset (4-5 independent samples for each 26 
tissue), light grey lines indicate missing values. FeLV viral RNA loads were tested for 27 
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significant differences by the non-parametric Friedmann test (pF), including only 1 
paired samples and the Dunn's Multiple Comparison test: * = p < 0.05; ** = p < 0.01; 2 
*** = p < 0.001. 3 
Figure 3  - FeLV viral RNA loads in different functional groups of tissues and in 4 
single tissues. 5 
Comparison of FeLV viral RNA loads among different response categories in A) the 6 
salivary glands (parotid and mandibular gland), B) the urinary tract (including the 7 
urinary bladder and the kidney), C) the mandibular gland and D) the urinary bladder. 8 
The FeLV viral RNA copy numbers are normalized to RPS7 cDNA copies. Similar 9 
results have been obtained with normalization to GAPDH cDNA copies (data not 10 
shown). The data are shown as box plots, and the boxes extend from the 25
th
 to 75
th
 11 
percentiles. The horizontal line represents the median, and the whiskers extend from 12 
the smallest to the largest value. FeLV viral RNA loads were tested for significant 13 
differences by Kruskal-Wallis one-way ANOVA by Ranks (pKW as indicated) and 14 
subsequently by Dunn's post test: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 15 
Figure 4  - FeLV provirus loads in tissues from different FeLV response 16 
categories. 17 
The FeLV provirus loads in 27 different tissues collected during necropsy from 18 
FeLV-infected cats grouped into four response categories were quantified using real-19 
time PCR: A) regressive cats, B) reactivated cats, C) viremic healthy cats and D) 20 
viremic ill cats. The FeLV provirus load was normalized using fALB. The data are 21 
shown as box plots, and the boxes extend from the 25
th
 to 75
th
 percentiles. The 22 
horizontal line represents the median, and the whiskers extend from the smallest to the 23 
largest value. The grey shading indicates the presence of a complete dataset (≥ 4 24 
independent samples for each tissue), and light grey lines indicate missing values. 25 
FeLV provirus loads were tested for significant differences by the non-parametric 26 
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Friedmann test (pF) including only paired samples and the Dunn's Multiple 1 
Comparison test: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 2 
Figure 5  - FeLV provirus loads in different functional groups of tissues and in 3 
single tissues. 4 
The FeLV provirus loads among the different response categories were compared in 5 
the A) salivary glands (parotid and mandibular gland), B) urinary tract (including the 6 
urinary bladder and the kidney), C) mandibular gland and D) urinary bladder. The 7 
FeLV provirus copy numbers were normalized to fALB. The data are shown as box 8 
plots, and the boxes extend from the 25
th
 to 75
th
 percentiles. The horizontal line 9 
represents the median, and the whiskers extend from the smallest to the largest value. 10 
FeLV provirus loads were tested for significant differences by Kruskal-Wallis one-11 
way ANOVA by Ranks (pKW as indicated) and subsequently by Dunn's post test: * = 12 
p < 0.05; ** = p < 0.01; *** = p < 0.001. 13 
 - 34 - 
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Table 1  – Duration and outcome of experimental FeLV infection in persistently viremic cats (FeLV-A/Glasgow-1) 
Cat ID Age at infection  
(weeks) 
Terminal age  
(years) 
Infection duration  
(years) 
Major diagnosis at necropsy Reference 
#HBZ3 10 1.8 1.6 Lymphoma (CD3
+
; CD79a
-
) in thymus, pericard, tonsils, and prescapular ln. [43]
2
 
#17 19 2.0 1.7 Lymphoma in mesenteric ln., intestines, liver, spleen, diaphragm, kidney [4]
2
 
#27 18 2.3 2.0 Lymphoma in the thymus, pericard and various ln.  [4]
2
 
#67
1
 17 2.6 2.3 Lymphoma in thymus, spleen, liver, various ln., and bm [4]
3
 
#264 59 3.7 2.6 Lymphoma in the intestines, including ln., spleen, kidney, and diaphragm [5]
2
 
#B3
1
 17 3.1 2.8 Lymphoma in the kidney and ln. of the gastrointestinal tract [42]
2
 
#B1
1
 18 3.8 3.4 Lymphoma in liver, diaphragm, ovary, gall bladder, mesenterium, 
peritoneum and uterus 
[42]
2
 
#Y4 17 4.2 3.8 Lymphoma in thymus [42]
2
 
#287 58 4.9 3.8 Lymphoma in the thymus, liver, bm, sporadic ln. [5]
2
 
#Y3 17 4.2 3.9 Lymphoma (CD3
-
; CD79a
-
) in liver, spleen, tonsils, and jejunum  [42]
2
 
#19
1
 19 4.5 4.1 Lymphoma in thymus, jejunum, ileum, mesenteric ln., and liver [4]
3
 
#32
1
 18 4.5 4.1 Lymphoma in thymus,  [4]
3
 
#272 59 6.6 5.5 Lymphoma in thymus, diaphragm, kidney, and mesenteric ln. [5]
2
 
#283 58 7.6 6.5 Lymphoma in kidney, liver, spleen, bm, several ln., anemia [5]
2
 
#63 17 2.2 1.8 Erythroleukemia  [4]
2
 
#M2 17 5.7 5.3 Acute lymphoblastic leukemia [42]
2
 
#276 59 6.4 5.3 Acute myeloid leukemia [5]
2
 
#HBW2 10 0.8 0.6 Nonregenerative anemia [43]
2
 
#25 19 1.0 0.6 Nonregenerative anemia [4]
2
 
#26 18 1.4 1.1 Nonregenerative anemia [4]
2
 
1 
These cats were also included in the tissue load study; 
2 
not vaccinated; 
3 
vaccinated with a whole virus vaccine (Fel-O-Vax, Fort Dodge, Iowa, USA).
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Table 2  – Tissue load study: Long-term outcome of FeLV infection in 19 experimentally FeLV-A/Glasgow-1 infected cats 
Cat ID Category Infection 
duration (y) 
p27 at euthanasia 
(%)
1
 
Outcome Reference 
#68 Regressive (2.5)
2
 0 Clinically healthy (end of experiment) [4]
3
 
#258 Regressive (12.7)
2
 0 Clinically healthy (end of experiment) [5]
4
 
#260 Regressive (12.7)
2
 0 Clinically healthy (end of experiment, finding upon necropsy: hydrometra) [5]
4
 
#271 Regressive (12.7)
2
 0 Clinically healthy (end of experiment) [5]
4
 
#B9 Regressive (4.5)
2
 0 Unrelated to FeLV-infection (foreign object) [42]
3
 
#30 Reactivated 1.0 25 Lymphoma in thymus  [4, 26]
5
 
#GCN4 Reactivated 1.2 132 Lymphoma in the thymus and inguinal ln. (CD3
+
; CD79a
-
) [40]
3
 
#HBU1 Reactivated 0.5 113  Lymphoma (CD3
+
; CD79a
-
) in thymus, mesenteric ln., liver, kidney & bm with 
secondary leukemia 
[43]
3
 
#261 Reactivated 8.5 53 Lymphoma in spleen, liver, kidney, ln., intestine, lung, etc. [5, 36]
4
 
#70 Reactivated 1.9 100 Lymphoma in the thymus, tonsil, spleen, kidney, various ln. [4, 26]
6
 
#15 Viremic healthy (0.9)
2
 65 Clinically healthy (end of experiment) [4]
6
 
#23 Viremic healthy (0.9)
2
 42 Clinically healthy (end of experiment) [4]
6
 
#64 Viremic healthy (0.9)
2
 55 Clinically healthy (end of experiment) [4]
5
 
#R1 Viremic healthy (0.4)
2
 39 Clinically healthy (end of experiment) [41]
3
 
#19 Viremic ill 4.1 154 Lymphoma around thymus, parts of the gastrointestinal tract, ln. & liver, hydrothorax [4]
6
 
#32 Viremic ill 4.1 207 Lymphoma in thymus, hydrothorax, atelectasis [4]
6
 
#67 Viremic ill 2.3 190 Lymphoma in thymus, spleen, liver and various ln. [4]
6
 
#B1 Viremic ill 3.4 72 Lymphoma in liver, diaphragm, ovary, gall bladder and uterus [42]
3
 
#B3 Viremic ill 2.8 168 Lymphoma in the kidney and ln. of the gastrointestinal tract  [42]
3
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1 
Values above 4% of the positive control were considered positive [4]; 
2
 The duration of the infection in cats with regressive infection and viremic healthy cats at the end of 
the experiment (tissue collection) is listed; 
3 
not vaccinated; 
4
 vaccinated with a recombinant protein vaccine (Leucogen, Virbac, Glattbrugg, Switzerland); 
5 
vaccinated with a 
recombinant canarypox-vectored vaccine (Purevax, Merial, Lyon, France); 
6 
vaccinated with a whole-virus vaccine (Fel-O-Vax, Fort Dodge, Iowa, USA).
 - 38 - 
Table 3  - Tissues investigated 
Tissue Group Tissue(s) 
Endocrine system 
Lymphoid tissues 
Thyroid 
bm, mesenteric ln., popliteal ln., sternal ln., submandibular ln., 
spleen, tonsil, thymus 
Salivary glands 
Intestinal tract  
Nervous system 
Urinary tract 
Parotid gland, mandibular gland 
Duodenum, ileum, jejunum, colon, rectum 
Brain, sciatic nerve, spinal cord 
Kidney, urinary bladder 
Muscle Diaphragm, femoral muscle, myocardium 
Others Lung, liver, aorta 
 
 
Supplementary files 
Supplementary file 1 - FeLV p27 antigen during FeLV infection in plasma of cats with 
different infection outcome  
Time course of FeLV infection in cats with A) regressive, B) viremic healthy and C) viremic ill 
infection. Results are represented as percentages of a defined positive control (plasma sample 
from a persistently FeLV-infected cat), which was considered 100%. Samples reaching > 4% of 
the positive control signal were considered positive [4]. 
Supplementary file 2 –Correlation between viral RNA and provirus loads. 
A) RNA and gDNA were extracted from tissue samples from 19 cats, and the viral RNA and 
DNA, respectively, were analysed by qPCR. A Spearman correlation was performed and 
indicated a strong correlation between viral RNA and DNA (r = 0.843, p < 0.0001). 
B) The ratios between all viral RNA and provirus loads are depicted for the different response 
categories. The data are shown as box plots, and the boxes extend from the 25
th
 to 75th 
percentiles. The horizontal line represents the median, and the whiskers extend from the smallest 
 - 39 - 
to largest value. Samples with undetectable loads were excluded from this analysis. Ratios were 
tested for significant differences by Kruskal-Wallis one-way ANOVA by Ranks (pKW as 
indicated) and subsequently by Dunn's post test: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
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